诚意药业：上半年净利润1.12亿元，同比增长47.03%

Core Insights - Chengyi Pharmaceutical (603811) reported its 2025 semi-annual results on August 26, showing a revenue of 417 million yuan, representing a year-on-year growth of 17.11% [1] - The net profit attributable to shareholders reached 112 million yuan, marking a significant year-on-year increase of 47.03% [1] - The basic earnings per share stood at 0.35 yuan, reflecting the company's strong financial performance [1] Revenue Growth - The increase in revenue is primarily attributed to the sustained growth in sales of joint-related medications [1]